Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Citomix
- Development stage
- Preclinical
- Lead developer
- Guna
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Peptides
- Administration
- Sublingual
01
Overview
Citomix is a multicomponent low-dose medicine (LDM) developed by Guna, formulated as a homeopathic preparation to modulate the immune system. It contains a combination of low-dose cytokines (such as IL-1, IL-2, IL-4, IL-6, and IFN-gamma) and growth factors (G-CSF) intended to regulate both humoral and cellular immune responses. The product is designed based on the principles of Physiological Regulating Medicine (PRM), which utilizes biological molecules at low concentrations to restore physiological homeostasis. Citomix is primarily used for the prevention and treatment of recurrent respiratory infections and is being investigated for its role in immune modulation following adenoid surgery in pediatric patients to reduce postoperative complications and support immune recovery.
- Brand names
- Citomix
02
Targets
IL-4 (Interleukin 4)IL-6 (Interleukin 6)IFNG (Interferon gamma)G-CSF (Granulocyte colony-stimulating factor)IL-2 (Interleukin 2)IL1B (Interleukin-1 beta)
Beyond the preview
Go deeper on Citomix.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Citomix.